Compare LGIH & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LGIH | GHRS |
|---|---|---|
| Founded | 2003 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 947.2M |
| IPO Year | 2013 | 2021 |
| Metric | LGIH | GHRS |
|---|---|---|
| Price | $40.56 | $21.54 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $75.90 | $41.38 |
| AVG Volume (30 Days) | ★ 415.7K | 255.2K |
| Earning Date | 04-28-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $1,705,504,000.00 | N/A |
| Revenue This Year | $2.32 | N/A |
| Revenue Next Year | $17.94 | N/A |
| P/E Ratio | $487.56 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $33.55 | $10.67 |
| 52 Week High | $69.42 | $24.66 |
| Indicator | LGIH | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 39.15 | 60.68 |
| Support Level | $34.71 | $12.41 |
| Resistance Level | $41.50 | $22.88 |
| Average True Range (ATR) | 2.33 | 1.33 |
| MACD | -0.64 | -0.07 |
| Stochastic Oscillator | 1.03 | 67.96 |
LGI Homes Inc is engaged in the design, construction, and sale of new homes in markets. The company's current product offerings include entry-level homes, including both detached homes and townhomes, and move-up homes sold, which are sold under the LGI Homes brand, and luxury series homes, which are sold under the Terrata Homes brand. It offers a set number of floor plans in each community with features that include upgrades, such as granite countertops, appliances, and ceramic tile flooring. The company has seven operating segments: West, Northwest, Central, Midwest, Florida, Southeast, and Mid-Atlantic. The majority of the revenue is generated from the Central division segment.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.